The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

13.1 - TAVI

Rivaroxaban after TAVI: GALILEO study


to compare the efficacy of rivaroxaban (10 mg daily) with aspirin (75-100 mg daily for the first 3 months) as compared to aspirin (75-100 mg daily) with clopidogrel (at a dose of 75 mg daily during the first 3 months) in patients with successful TAVR


open label, event-driven multicentre randomised study


patients with successful TAVR and no established indication for long term anticoagulation


composite of all-cause death or thromboembolic events (stroke, MI, valve thrombosis, embolism, deep vein thrombosis or pulmonary embolism). Safety endpoint: composite of life threatening, disabling or major bleeding during median 17 months




a treatment strategy of anticoagulation after TAVR including rivaroxaban (10 mg daily) was associated with higher adverse events and bleeding rates than antiplatelet based strategy

Dangas et al. N Eng J Med. 2020;382:120-29

View next trial
Everolimus-eluting vs biolimus-eluting stents with biodegradable polymers: SORT-OUT VIII Trial

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from